First New York Securities’s Catalyst Pharmaceutical CPRX Stock Holding History

First New York Securities’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-7,500	Closed	-$24.9K	–	388
2014 Q3	$24.9K	Buy	+7,500	New	+$19.6K	0.02%	318

Other funds holding CPRX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

CCA

Catalyst Capital Advisors Huntington, New York $5.37B AUM 18.53% 1-Year Est. Return

PCA

Private Capital Advisors Darien, Connecticut $872M AUM 26.12% 1-Year Est. Return

First New York Securities's CPRX Position: Q4 2014 in Review

First New York Securities sold out of Catalyst Pharmaceutical (CPRX) in Q4 2014, closing a stake of 7,500 shares — an estimated $24.9K sold.

First New York Securities first reported a position in CPRX in Q3 2014 and held it in 1 quarter. The position peaked at $24.9K in Q3 2014. 50 funds tracked by Wall St. Rank hold CPRX as of Q4 2014.

First New York Securities reported no remaining Catalyst Pharmaceutical position as of Q4 2014 after selling out during the quarter.
First New York Securities sold 7,500 Catalyst Pharmaceutical shares in Q4 2014, an estimated $24.9K.
First New York Securities first reported a position in Catalyst Pharmaceutical in Q3 2014 and held it in 1 quarter.
First New York Securities's Catalyst Pharmaceutical position peaked at $24.9K in Q3 2014.
50 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2014.

Based on First New York Securities's 13F filing for Q4 2014, filed 9 Jan 2015.